Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ionis Pharmaceuticals IncfiledCriticalIonis Pharmaceuticals Inc
Priority claimed from PCT/US2014/036463external-prioritypatent/WO2014179627A2/en
Publication of MA38621A1publicationCriticalpatent/MA38621A1/en
Publication of MA38621B1publicationCriticalpatent/MA38621B1/en
L'invention concerne des composés oligomères à groupes conjugués. Dans certains modes de réalisation de l'invention, ces composés oligomères sont conjugués à la n-acétylgalactosamine.The invention relates to oligomeric compounds with conjugated groups. In certain embodiments of the invention, these oligomeric compounds are conjugated to n-acetylgalactosamine.
MA38621A2013-05-012014-05-01
Compositions and methods for modulating the expression of hbv and ttr
MA38621B1
(en)
Compounds derived from pyrrolo1,2-f1,2,4triazine, a pharmaceutical composition that comprises them and their use in the treatment of a syncytial virus infection intermediary compounds. pct